Sunscreen formulations comprising microcapsules and methods of making such microcapsules

The UV filter is encapsulated through microencapsulation technology, and the core-shell microcapsules of crosslinked polymer shells are used to solve the problem of light instability of the UV filter in existing sunscreen preparations and the problem of cross-sectional barriers, achieving efficient UV protection and aesthetic use effects.

CN120225161APending Publication Date: 2025-06-27EXOSHIELD

Patent Information

Application Number
CN202380077746.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-11-08
Filing Date
2023-11-08
Publication Date
2025-06-27

AI Technical Summary

Technical Problem

Among the existing sunscreen preparations, many organic UV filters have light instability, allergic potential and ability to cross the skin barrier, while mineral UV filters are difficult to formulate and leave unsightly marks on the skin.

Method used

Microencapsulation technology is used to prepare core-shell microcapsules through interface polymerization, encapsulate UV filters, and use crosslinked polymer shells to provide mechanical strength and waterproof performance to ensure stable distribution of microcapsules on the skin.

Benefits of technology

It achieves efficient protection in UVA and UVB spectra, preventing UV filters from passing through the skin barrier, improving aesthetics, reducing white marks, and improving sunscreen factor SPF.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005391069660000181
    Figure BDA0005391069660000181
  • Figure BDA0005391069660000201
    Figure BDA0005391069660000201
  • Figure BDA0005391069660000221
    Figure BDA0005391069660000221
Patent Text Reader

Abstract

Disclosed is a core-shell microcapsule comprising a core containing at least one active ingredient and a shell forming a wall surrounding the core and making up at least 20% by mass of the total mass of the microcapsule, said microcapsule being characterized in that the shell comprises at least one cross-linked polymer, the at least one cross-linked polymer is preferably obtained by interfacial polymerization. The size of the microcapsules is preferably less than 1 [mu] m. The active ingredient may be a sunscreen.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of cosmetology and more particularly to sunscreen preparations intended for application to the skin and containing substances called sunfilters or preparations providing protection against photoaging of the skin or skin appendages. These preparations can exist in particular in the form of liquid or pasty emulsions such as ointments, creams, lotions, foams; or in the form of solid emulsions such as sticks, bars, loaves; or in a non-emulsified form such as oils, suspensions, gels, lotions, loose or compact powders.

[0002] More specifically, the present invention relates to preparations microencapsulated in a thick shell formed of a crosslinked polymer. The size of these microcapsules is in the submicron range. Background Art

[0003] Sunscreen preparations or products purporting to prevent photoaging of the skin and skin appendages include specific molecules capable of attenuating the ultraviolet rays (commonly abbreviated as "UV") of the solar spectrum. This attenuation is achieved by the absorption or reflection, in whole or in part, by the molecules (referred to herein as ultraviolet filters) of at least a portion of the near-ultraviolet spectrum. It is well known that, in general, UV rays are harmful to the skin, particularly those belonging to two spectral regions designated by those skilled in the art as "UV-A" (from about 320 nm to 400 nm) and "UV-B" (from about 280 nm to 320 nm). The shortest wavelength ultraviolet rays are the most aggressive, while the longer wavelength ultraviolet rays penetrate deeper into the skin. They can cause immunosuppression and skin cancer. More specifically, UV-A rays induce immediate skin pigmentation and also induce premature aging (photoaging). UV-B rays induce the synthesis of vitamin D in the skin and delay skin pigmentation (tanning), but also cause sunburn.

[0004] The most effective UV filters can protect against both UV-A and UV-B rays. There are organic UV filters and mineral UV filters.

[0005] Organic UV filters (also called chemical UV filters) are organic molecules that absorb and dissipate UV rays through chemical reactions. Most of these organic UV filters are lipophilic. The maximum concentration of organic UV filters and their mutual combinations with sunscreen preparations or products purporting to prevent photoaging of the skin and skin appendages are regulated. Examples of organic UV filters include benzophenone, octocrylene, avobenzone, octyl methoxycinnamate. Organic UV filters have the advantage of being easily incorporated into user-friendly sunscreen preparations.

[0006] However, some organic UV filters have drawbacks, including photo-instability (e.g., avobenzone), the potential for allergy (e.g., alkyl esters of p-aminobenzoic acid), and many of them have the ability to cross the skin barrier (stratum corneum) (e.g., ethylhexyl methoxycinnamate), and may exhibit endocrine disrupting effects (e.g., oxybenzone). For example, in the United States, if the concentration of these molecules is found to be greater than 0.5 ng / mL in plasma, the U.S. Food and Drug Administration (FDA) now requires additional toxicological studies on organic sunscreens.

[0007] Finally, although all of these molecules are lipophilic, they eventually enter the natural environment where they represent an increasingly unacceptable chemical pollution. For example, two molecules commonly used as UV filters (i.e., benzophenone-3 and ethylhexyl methoxycinnamate) are considered toxic to the aquatic environment, and some local governments (e.g., the state of Hawaii in the United States) have banned or restricted the use of sunscreen formulations containing these molecules.

[0008] Mineral UV filters are typically made from poorly soluble inorganic powders (e.g., titanium dioxide, zinc oxide, cerium oxide, or iron oxide). These particles reflect UV-A and UV-B rays. These powders must be dispersed. To facilitate their incorporation into sunscreen formulations, the inorganic particles are usually coated with hydrophilic or hydrophobic coatings (e.g., based on methoxysilane, polydimethylsiloxane, silica, or alumina). This coating partially inhibits their photoreactivity because these powders are metal oxides that can release hydrogen peroxide (H2O2) into water through photocatalytic reactions. It is responsible for damaging biological substances (zooplankton).

[0009] Mineral UV filters have the advantages of low allergenicity and not crossing the skin barrier. On the other hand, they are more difficult to formulate than organic UV filters because sunscreen formulations incorporating these UV filters or products claiming to prevent photoaging of the skin and skin appendages are usually thicker and tend to leave unsightly white marks on the skin. To overcome this problem, the particle size of these mineral UV filters can be reduced by making them nanosized. This improves the sun protection performance, but regulations then require specific labeling and prohibit formulation in an evaporable or aerosol form.

[0010] Sunscreen formulations or products claiming to prevent photoaging of the skin and skin appendages are typically characterized by their sun protection factor (abbreviated as SPF), which is defined according to the following formula:

[0011] SPF = (Minimum erythema dose on protected skin) / (Minimum erythema dose on unprotected skin)

[0012] Sun protection preparations containing UV filters or products purporting to prevent photoaging of the skin and skin appendages must meet numerous requirements in order to be most effective in providing photoprotection. In particular, these preparations must have low penetration of the active substances (such as UV filters) into the skin to limit toxicity or allergy problems. The preparation must also have good emollient properties to allow for a pleasant and lasting application to the skin surface. They are also expected to be film-forming and waterproof, rather than sticky, especially since repeated application is recommended during sun exposure.

[0013] According to the prior art, sun protection compositions or products for preventing photoaging of the skin and skin appendages can exist in different types of preparations, among which we can list the following forms: liquid or pasty emulsions, namely ointments, creams, lotions, foams; or solid emulsions, namely sticks, bars, loaves; or non-emulsified forms, namely oils, suspensions, gels, lotions, loose or compact powders. The formulation of sun protection products depends on the physicochemical properties of the incorporated UV filters. When the photoprotection product is an emulsion, it contains a lipid phase, an aqueous phase and one or more surfactants. If the UV filters are lipophilic, they are dispersed in the lipid phase, or if the UV filters are hydrophilic, they are dispersed in the aqueous phase. It is known to add excipients to sun protection preparations to ensure the optimal distribution of UV filters on the skin surface by forming a uniform protective film upon application.

[0014] Generally speaking, it is not desirable for UV filters to penetrate the skin as they may be toxic or sensitizing. These two phenomena can be caused or enhanced by the action of UV light, which can make these filters phototoxic or photoallergic; if these filters are photo-unstable, their decomposition products will also exhibit these undesirable effects.

[0015] The penetration of UV filters through the skin can be promoted in particular by: poor general skin condition; the breakdown of the lipids of the skin barrier under the action of UV rays; the presence of certain solvents (such as ethanol, propylene glycol), surfactants; the presence of certain emollients, alpha-hydroxy acids (commonly abbreviated as AHA); and the molecular weight of the filter, it being known that molecules with a molecular weight of less than 500 Da are more likely to cross the skin barrier than molecules with a higher molecular weight.

[0016] However, according to the prior art, organic UV filters are generally low molecular weight lipophilic molecules; thus, they may pass through the skin barrier, reach the nucleated cells of the skin, and then reach the systemic circulation. To limit this passage through the skin barrier, the prior art provides formulations of sunscreen products or products claiming to prevent photoaging of the skin and skin appendages, in which the UV filters are trapped in particles. In particular, many embodiments are known in which the UV filters are encapsulated in microcapsules. These particles can also absorb and / or reflect UV radiation. The outer wall of these particles can be selected from materials that allow the integrity of the sunscreen mixture to be maintained by adequate sealing; it is desirable that such materials are stable under solar radiation to allow for an extended effect of application.

[0017] The prior art includes many particulate systems. For example, we know solid lipid nanoparticles (SLN). These SLN are oily droplets of lipids that are solid at body temperature and stabilized by surfactants. In other words, SLN are nanoparticles composed of a solid lipid core encapsulated by one or more surfactants suspended in an aqueous phase; thus, SLN have encapsulation properties that can enable them to be used in cosmetic sunscreen products. Therefore, formulations containing SLN can be prepared in which lipophilic UV filters are encapsulated; with these formulations, the penetration of the encapsulated UV filters into the skin will be reduced. Such compositions are described in US Patent Application 2003 / 0235540.

[0018] However, the use of SLN has the following disadvantages: on the one hand, the amount of encapsulated UV filter is limited, and on the other hand, these nanoencapsulated systems are not completely stable: during the storage of the sunscreen formulation, the UV filters tend to be expelled from the nanoparticles. This latter problem is inherent in the solid lipid constituting the SLN matrix, which tends to form a perfect crystalline network, the voids of which allow the expulsion of the UV filters from the nanoparticles.

[0019] In addition, depending on the melting point of the solid lipid matrix used, SLN can be more or less heat-sensitive. If the solid lipid matrix melts, this can disrupt the system, which may lead to a decrease in the UV filtering ability of the SLN, but also to a total phase shift of the SLN suspension. Finally, the significant presence of solid lipids with a melting point higher than skin temperature (i.e., higher than about 32 °C) makes it difficult to spread SLN-based sunscreen formulations.

[0020] Therefore, considering the prior art knowledge regarding the properties of SLN, sunscreen formulations containing UV filters encapsulated using this system have not proven to be entirely satisfactory.

[0021] UV filter capture systems are also known, which consist of nanoparticles made of solid lipids and a liquid lipid core encapsulated by one or more surfactants, and the nanoparticles are obtained by mixing solid lipids and liquid lipids. These particles that can be suspended in the aqueous phase are called nanostructured lipid carriers (NLCs). Compared with SLNs, NLCs have a heterogeneous structure, which gives their matrix an imperfect structure with spaces that can accommodate UV filters. This overcomes the problem of UV filter expulsion encountered by SLNs. However, due to the presence of solid lipids, NLCs exhibit the same type of spreading defects and thermal sensitivity as SLNs.

[0022] Although their greater ability to encapsulate UV filters and better stability make NLCs more suitable for the field of formulating sunscreen products or anti-photoaging products, their stability during storage and after spreading on the skin is still not entirely satisfactory.

[0023] Another method is represented by nanocapsules, which contain an oily core and a UV filter surrounded by a polymer coating (also called a shell); this method is described in many documents, such as FR 3 009 682 (Polaar SAS and Université Claude Bernard Lyon 1). These polymer shells can have different properties.

[0024] For example, document WO 2009 / 091726 (Dow Global Technologies) describes the encapsulation of hydrophobic sunscreen molecules in a polyurea shell obtained by interfacial polymerization of isocyanate and amine. The optimal shell thickness depends on the diameter of the microcapsules: for diameters up to 4 μm, the shell thickness must be greater than 10 nm, while for sizes greater than 10 μm, the shell thickness must be at least 100 nm.

[0025] WO 2013 / 059166 (Dow Global Technologies) describes a microencapsulated sunscreen agent in which the UV filter is encapsulated in polymer microcapsules obtained by the reaction of an isocyanate prepolymer with water to form a polyurea shell. These microcapsules can be less than 1 μm, and regarding their thickness, the teachings of this document are similar to those of the previous document.

[0026] WO 2014 / 132261 (Tagra Biotechnologies) describes microcapsules containing a UV filter and formed from polyacrylate, polymethacrylate, cellulose ether, cellulose ester or a mixture of these polymers. WO 2012 / 004461 (Biosynthis) describes microcapsules containing a UV filter and formed by the polymerization of methyltrimethoxysilane or methyltriethoxysilane.

[0027] There is a need for UV filter encapsulation systems and sunscreen product formulations with improved sun protection properties, while coordinating several other parameters, such as: a minimum UVA / UVB intensity ratio of 33% for UVA protection on the skin and a good distribution of the sunscreen between UVA and UVB with a critical wavelength greater than 370 nm; preventing percutaneous passage of the UV filter; improved aesthetic properties, such as reducing the white marks left on the skin, especially by mineral UV filters, after application.

[0028] There is also a desire for sunscreen formulations that use as few substances, called sunscreens, as possible to achieve a given sun protection factor.

[0029] The present invention aims to provide a cosmetic formulation comprising a microencapsulated UV filter that provides protection in the UVA and UVB spectra and thus meets all these requirements. Summary of the Invention

[0030] The present invention proposes to meet these above requirements by selecting core-shell microcapsules that comprise a shell encapsulating at least one active substance, and the core-shell microcapsules are very small in size, i.e., their D S50 value does not exceed 1 μm, preferably less than 1.0 μm, preferably remaining less than 0.80 μm, but they only penetrate up to the stratum corneum (i.e., the upper layer of the epidermis). These microcapsules also have water-repellent properties and mechanical strength in terms of resistance to crushing and friction, without giving a sticky appearance to the cosmetic composition comprising the microcapsules. This strength is achieved by using a crosslinked polymer for the shell and a sufficient thickness of the shell that accounts for at least 20% of the total mass of the microcapsules.

[0031] The microcapsules of the present invention can be obtained by interfacial polymerization (in particular by interfacial polymerization of precursors of polyurea-type macromolecular compounds) in order to encapsulate an active substance (such as a sunscreen).

[0032] The present invention relates to cosmetic and / or dermatological and / or pharmaceutical compositions comprising microcapsules according to the invention, in particular sunscreen compositions or compositions claimed to prevent photoaging of the skin or skin appendages, preferably water-resistant compositions. These formulations may be emulsions; in particular, they may be formulations of the "water-in-oil emulsion" or "oil-in-water emulsion" type. In the context of the present invention, a composition comprising microcapsules according to the invention, preferably a sunscreen cosmetic or a cosmetic claimed to prevent photoaging of the skin or skin appendages, may be formulated in particular in the form of a liquid or pasty emulsion, i.e. an ointment, a cream, a lotion, a foam; or in the form of a solid emulsion, i.e. a stick, a bar, a boule; or in a non-emulsified form, i.e. an oil, a suspension, a gel, a lotion, a loose or compact powder, and more generally, the composition is formulated with other active ingredients in the form of a bath gel, a shampoo, etc.

[0033] A first object of the present invention is a core-shell microcapsule comprising a core and a shell, the core containing at least one active ingredient, the shell constituting a wall surrounding the core and having a mass fraction of at least 20%, preferably at least 25%, more preferably at least 28%, even more preferably at least 30%, even more preferably at least 32% (or even at least 35%) of the total mass of the microcapsule, the microcapsule being characterized in that the shell comprises at least one crosslinked polymer. The microcapsules are preferably prepared by interfacial polymerization.

[0034] The crosslinked polymer is advantageously selected from polyurethanes and / or polyureas. The shell may also comprise an anionic surfactant (preferably an alkyl ether sulfate) and / or at least one nonionic surfactant, such as an ester or ether of polyethylene glycol, a polyglycerol ester, an ester of a sorbitol derivative, such as sorbitan stearate, a sucrose ester or a polysorbate (such as polysorbate 20, polysorbate 40 or polysorbate 60). Polysorbate 20 is the preferred nonionic surfactant. Advantageously, the core is liquid.

[0035] A second object is the use of the core-shell microcapsules according to the invention in the preparation of a sunscreen formulation or a formulation providing protection against photoaging of the skin and skin appendages. The formulation is preferably capable of being used in the form of a liquid or pasty emulsion (such as an ointment, a cream, a lotion, a foam), or in the form of a solid emulsion (such as a stick, a bar, a boule), or in a non-emulsified form (such as an oil, a suspension, a gel, a lotion, a loose or compact powder).

[0036] A third object of the present invention is a sunscreen or anti-photoaging preparation containing a plurality of core-shell microcapsules according to the present invention. The preparation is particularly in the form of: a liquid or pasty emulsion (such as an ointment, cream, lotion, foam), or a solid emulsion (such as a stick, bar, loaf), or a non-emulsified form (such as an oil, suspension, gel, lotion, loose or dense powder), and the preparation contains a plurality of microcapsules according to the present invention. Advantageously, relative to the total weight of the preparation, the sunscreen or anti-photoaging preparation contains at least 5% by mass, preferably at least 10% by mass, more preferably at least 20% by mass, even more preferably at least 30% by mass, and even more preferably at least 35% by mass of core-shell microcapsules.

[0037] The sun protection factor SPF of the sunscreen or anti-photoaging preparation according to the present invention can be at least 10, preferably at least 15, more preferably at least 30, even more preferably at least 40, and optimally at least 50.

[0038] Yet another object of the present invention is a method for preparing core-shell microcapsules by interfacial polymerization, the core-shell microcapsules comprising a core and a shell, the core containing at least one active ingredient, the shell constituting a wall surrounding the core, the shell accounting for at least 20% by mass, preferably at least 25% by mass, even more preferably at least 30% by mass, and even more preferably at least 35% by mass of the total mass of the microcapsules, and the shell containing at least one crosslinked polymer obtained from at least two precursor compounds A and B.

[0039] The method comprises the steps consisting of:

[0040] (a) Mixing the at least one active ingredient, a solvent, and at least one compound A to obtain a lipophilic phase, the at least one compound A containing more than two functional groups A';

[0041] (b) Introducing the lipophilic phase obtained in step (a) into an aqueous continuous phase with stirring to form an emulsion, the aqueous continuous phase preferably containing NaCl;

[0042] (c) Maintaining the emulsion at a temperature between about 35°C and about 90°C, preferably between about 40°C and about 70°C, and even more preferably between about 55°C and about 65°C with stirring, and introducing an aqueous solution containing at least one compound B containing more than two functional groups B' into the emulsion obtained at the end of step (b) with stirring, so that the functional groups A' of the compound A containing more than two functional groups A' react with the functional groups B' of the compound B containing more than two functional groups B' to form a crosslinked polymer shell constituting the wall surrounding the core, thereby obtaining core-shell microcapsules.

[0043] In a preferred embodiment, the stirring during step (b) is performed at a tangential velocity greater than that during the introduction of the aqueous solution containing at least one compound B in step (c), and preferably at a tangential velocity of at least 10 m / s, even more preferably between 10 m / s and 30 m / s.

[0044] In a preferred embodiment of the present method, the aqueous continuous phase contains at least one anionic surfactant and / or one non-ionic surfactant, and the anionic surfactant is preferably selected from alkyl ether sulfates, and even more preferably selected from magnesium laureth sulfate and sodium laureth sulfate.

[0045] In another embodiment of the present method, which can be combined with the foregoing and other embodiments described herein, the NaCl content in the emulsion obtained in step (b) is between 0.10% and 1% by mass, preferably between 0.15% and 0.90% by mass.

[0046] In yet another embodiment, which can be combined with the foregoing and other embodiments described herein, the crosslinked polymer is selected from polyureas or polyurethanes.

[0047] Another object of the present invention is a method for manufacturing core-shell microcapsules by interfacial polymerization, the core-shell microcapsules comprising a core and a shell, the core containing at least one sunscreen agent, the shell constituting a wall surrounding the core, the shell containing a crosslinked polymer and at least one alkyl ether sulfate, the method comprising the following steps:

[0048] (a) Mixing the at least one sunscreen agent, a solvent, and a compound A containing more than two functional groups A' (a precursor of the crosslinked polymer shell constituting the wall surrounding the core) to obtain a lipophilic phase;

[0049] (b) Under stirring, introducing the lipophilic phase obtained in step (a) into an aqueous continuous phase containing NaCl and at least one alkyl ether sulfate to form an emulsion;

[0050] (c) Maintaining the emulsion at a temperature between about 35 °C and about 90 °C, preferably between about 40 °C and about 70 °C, even more preferably between about 55 °C and about 65 °C, under stirring, and introducing an aqueous solution containing a compound B containing more than two functional groups B' into the emulsion obtained at the end of step (b) under stirring, so that the functional groups A' of the compound A containing more than two functional groups A' react with the functional groups B' of the compound B containing more than two functional groups B' to form a crosslinked polymer shell constituting the wall surrounding the core, thereby obtaining core-shell microcapsules. Description of the Drawings

[0051] Figures 1 to 12They relate to the present invention and illustrate different aspects thereof.

[0052] Figure 1 Relates to Example 1 and shows the particle size distribution of a batch of microcapsules 108 expressed in terms of number (curve (A)), surface area (curve (b)), and volume (curve (c)).

[0053] Figure 2 Relates to Example 1 and shows the particle size distribution of a batch of microcapsules 110 expressed in terms of number (curve (a)), surface area (curve (b)), and volume (curve (c)).

[0054] Figure 3 Relates to Example 1 and compares the surface area particle size distribution between sample 108 (curve (a)) and sample 110 (curve (b)).

[0055] Figure 4 Relates to Example 3 and shows the function of SPF (sun protection factor) versus the diameter (denoted as D S50 ) of the surface area weighted distribution of microcapsules according to the present invention, with all other conditions being the same.

[0056] Figure 5 Relates to Example 4 and shows the volume weighted D V50 particle size distribution of microcapsules in the slurry.

[0057] Figure 6 Relates to Example 4 and shows the surface area weighted D Figure 5 particle size distribution of microcapsules in the same slurry prepared S50 .

[0058] Figure 7 Relates to Example 4 and shows the ζ potential representing the charge state of the particle surface in the colloid.

[0059] Figure 8 Relates to Example 5 and shows the function of light stability versus the number of irradiations (at 30 - minute intervals) for a composition according to the present invention containing approximately 25% UV filter (curves c and d) and a non - microencapsulated composition according to the prior art containing the same concentration of the same active ingredient (curves a and b).

[0060] Figure 9 Relates to Example 5 and shows the function of light stability versus the number of irradiations (at 30 - minute intervals) for a composition according to the present invention containing approximately 35% UV filter (curves c and d) and a non - microencapsulated composition according to the prior art containing the same concentration of the same active ingredient (curves a and b).

[0061] Figure 10 ​​​​​​​​Relates to Example 5 and shows the SPF factor as a function of the UV filter concentration of the microencapsulated composition according to the invention (curve a) and of the non-microencapsulated composition containing the same active ingredient at the same concentration (curve b).

[0062] Figure 11 Relates to Example 6 and shows fluorescence micrographs (magnification: 20) of human skin explant samples prepared in a cryostat. On the left is a sample taken from untreated skin, in the middle is a sample taken from skin treated with a non-microencapsulated preparation, and on the right is a sample taken from skin treated with a microencapsulated preparation according to the invention.

[0063] Figure 12 Relates to Figure 11 and shows the total intensity of the images at a magnification of 20 (right) and at a magnification of 10 (left). DETAILED DESCRIPTION

[0064] Unless otherwise indicated, all percentage values refer to mass. Unless otherwise indicated, all D50 values are D S50 value: median size or D S50 size is the size at which the cumulative function is equal to 50%; it is surface area weighted. The choice of surface area weighting is the most relevant when studying the activity of a given dispersed component, as described in the context of the present application.

[0065] The microcapsules according to the invention have a liquid core representing the active substance to be encapsulated and a shell made of a crosslinked polymer material. The crosslinked polymer is selected from polyureas and / or polyurethanes. The active substance comprises at least one active substance selected from UV filters.

[0066] We first describe the manufacture of the microcapsules.

[0067] According to the invention, these microcapsules are prepared by an interfacial polymerization method.

[0068] In a first step (hereinafter also referred to as "step (a)"), the active ingredient to be encapsulated, which is intended to form the liquid core of the microcapsules, is mixed with a solvent (if necessary) and a compound A comprising more than two functional groups A', where the compound A is one of the precursors of the crosslinked polymer shell forming the wall around the core. This gives a lipophilic phase, i.e. a phase immiscible with water.

[0069] In a second step (also referred to herein as "step (b)"), the lipophilic phase obtained at the end of the first step is introduced into the aqueous continuous phase with stirring to form an emulsion.

[0070] The aqueous continuous phase preferably contains NaCl.

[0071] ​In the third step (also referred to herein as "step (c)"), the emulsion is maintained under stirring at a temperature between about 35°C and about 90°C, preferably between about 40°C and about 70°C, even more preferably between about 55°C and about 65°C, and an aqueous solution containing compound B with more than two functional groups B' is introduced under stirring into the emulsion of compound B obtained at the end of step (b) so that the functional groups A' of compound A containing more than two functional groups A' react with the functional groups B' of compound B containing more than two functional groups B'. The product of this reaction is a crosslinked polymer. It forms the shell or wall of the microcapsules. This results in core-shell microcapsules that contain a crosslinked polymer shell constituting the wall around the liquid core. Generally, the reaction medium is continuously stirred until all monomers (especially isocyanates) are consumed.

[0072] The progress of this process requires some control of the temperature of the reaction mixture. The temperature depends on the reactivity of the monomers or prepolymers used and the stirring.

[0073] In a very advantageous embodiment of the present invention, the stirring during step (b) is carried out at a tangential velocity greater than that during step (c), and preferably at a tangential velocity of at least 10 m / s, preferably between 10 m / s and 30 m / s. It should be noted that, generally speaking, the number of revolutions of the rotor per unit time is not a parameter suitable for characterizing the shear experienced by the liquid phase stirred by this rotor. The tangential velocity of the extreme points of the rotor best and simply describes the shear in the emulsion chamber.

[0074] According to the present invention, step (b) requires strong stirring to ensure strong shear. This stirring is obtained in a known manner by using a rotor and is characterized in a simple way by the tangential velocity of the rotor. This strong shear is advantageously obtained at a tangential velocity of at least about 10 m / s, advantageously between about 10 m / s and about 30 m / s. When it is lower than about 10 m / s, the obtained microcapsules have too large a diameter, thus not allowing the benefit of using a small diameter. When it is higher than about 30 m / s, it becomes difficult to control the emulsion temperature due to excessive local heating of the rotor-stator shear. Preferably, the tangential velocity is between about 10 m / s and about 28 m / s, more preferably between about 15 m / s and about 25 m / s, even more preferably between about 15 m / s and about 23 m / s.

[0075] The third step generally starts during the adjustment of the temperature of the mixture to a desired value, preferably while maintaining the reaction mixture under vigorous stirring, i.e., at least initially within the same limits as in the second step. The addition of the aqueous solution containing at least one compound B in step (c) is carried out under stirring, the stirring being characterized by a tangential velocity less than that during step (b). Thus, a tangential velocity between about 1 m / s and about 6 m / s is suitable when adding compound B; preferably, the tangential velocity is between about 2 m / s and about 5 m / s. The duration of the third stage must be sufficient for the formed emulsion to have the desired fineness and uniformity, such that it is known that during the polymerization process, the formed microcapsules have dimensions comparable to the emulsion droplets.

[0076] In order for the addition of the aqueous solution to be carried out within the target temperature range during step (c), it is generally necessary to regulate the temperature. In particular, the dispersed phase and / or the aqueous continuous phase can be preheated during step (b), and / or the emulsion can also be heated at the start of step (b). Since the shear of the emulsion provides heat energy, it may be necessary to cool the emulsion in some cases. For the temperature management during the polymerization reaction in step (b), the exothermic nature of the reaction must be taken into account.

[0077] Advantageously, the emulsion at the end of step (b) is transferred to a different reactor, which is provided on the one hand with a stirring device different from that of the reactor in which step (b) takes place, and on the other hand with a specific heat exchange device.

[0078] The process can be carried out in different ways.

[0079] According to one embodiment, in the second step, the lipophilic phase is brought to a temperature between about 35 °C and about 90 °C, preferably between about 40 °C and about 70 °C, even more preferably between about 55 °C and about 65 °C; in the third step, the temperature of the aqueous continuous phase is between about 35 °C and about 90 °C, preferably between about 40 °C and about 70 °C, even more preferably between about 55 °C and about 65 °C.

[0080] Advantageously, in the third step, the temperature of the aqueous solution is similar to the temperature of the emulsion. Preferably, the difference in their temperatures does not exceed 15 °C, preferably does not exceed 10 °C, even more preferably does not exceed 5 °C.

[0081] Advantageously, the core of the microcapsules is liquid. The aqueous continuous phase can contain at least one anionic surfactant and / or at least one non-ionic surfactant. Advantageous anionic surfactants can be selected from the group consisting of: sodium lauryl sulfate, C 14 -C 16Sodium olefin sulfonate, sodium lauryl polyether sulfate, disodium lauryl polyoxyethylene ether sulfosuccinate, sodium cocoyl methyl taurate, sodium cocoyl hydroxyethyl sulfonate, sodium lauroyl sarcosinate, sodium lauroyl glycinate, sodium lauroyl lactate, magnesium lauryl polyether sulfate, TEA - lauryl sulfate, sodium lauroyl glutamate, sodium lauryl polyether carboxylate, sodium lauryl polyether phosphate, sodium lauryl sulfoacetate, hydrogenated lecithin; these names are known as INCI (International Nomenclature of Cosmetic Ingredients) names.

[0082] In particular, the anionic surfactant may comprise an alkyl ether sulfate. A particularly advantageous surfactant comprises disodium 2 - sulfolaurate; a trademark for one such product is known as Texapon TM 。

[0083] Preferably, non - ionic surfactants are used, which can be polyethylene glycol esters or ethers, polyglycerol esters, esters of sorbitol derivatives (such as sorbitan stearate), sucrose esters or alkyl ether sulfates or polysorbates (such as polysorbate 20 (polyoxyethylene sorbitan monolaurate), also known as Tween TM 20, polysorbate 40 or polysorbate 60). Advantageously, the non - ionic surfactant can be selected from the group consisting of: poloxamer 407, poloxamer 188, oleth - 10, oleth - 20, laureth - 23, laureth - 4, PEG - 40 hydrogenated castor oil, PEG - 60 hydrogenated castor oil, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, sorbitan oleate, sorbitan stearate, sorbitan palmitate, sorbitan myristate, sorbitan laurate, gluceth - 20, PEG - 7 glyceryl cocoate, PEG - 6 caprylic / capric glycerides, PPG - 1 - PEG - 9 lauryl glycol ether, heptyl glucoside, polyglyceryl - 10 laurate, glyceryl oleate, polyglyceryl - 4 oleate, polyglyceryl - 4 oleate, PEG / PPG - 20 / 23 dimethicone, PEG / PPG - 23 / 6 dimethicone, PEG - 8 dimethicone, dimethicone PEG - 10 phosphate, sucrose laurate, sucrose palmitate; these names are known as those INCI names.

[0084] These surfactants are located in the shell after polymerization.

[0085] According to an advantageous embodiment, the aqueous continuous phase used in this third step comprises at least one alkyl ether sulfate. For this purpose, magnesium lauryl polyether sulfate and sodium lauryl polyether sulfate are preferred.

[0086] According to another advantageous aspect of the invention, the NaCl content in the aqueous continuous phase used in step (b) is selected such that the NaCl content of the emulsion obtained at the end of this step (b) is between 0.10% and 1% by mass, preferably between 0.15% and 0.90% by mass. The addition of NaCl allows for a more concentrated suspension without aggregates.

[0087] According to an essential feature of the invention, the shell comprises at least one crosslinked polymer. This results in microcapsules exhibiting good mechanical robustness. Therefore, it is necessary to select suitable monomers or oligomers that enable the obtaining of a crosslinked polymer. The functional group A' of compound A containing more than two functional groups A' is selected from isocyanate groups, in particular from polyisocyanates, which are molecules containing two or more isocyanate groups, such as diisocyanates. Preferred are diisocyanates and triisocyanates, the isocyanate groups of which can be linked to an aliphatic or aromatic backbone. The aliphatic polyisocyanates can be selected from aliphatic polyisocyanates containing two, three or more isocyanate functional groups or mixtures of these polyisocyanates. Preferably, the aliphatic polyisocyanates contain one or more cycloalkyl backbones.

[0088] For example, compound A can be selected from the group consisting of:

[0089] - Dicyclohexylmethane 4,4'-diisocyanate, hexamethylene 1,6-diisocyanate, isophorone diisocyanate, trimethyl-hexamethylene diisocyanate, trimer of hexamethylene 1,6-diisocyanate, trimer of isophorone diisocyanate, 1,4-cyclohexane diisocyanate, 1,4-(dimethylisocyanatyl)cyclohexane, hexamethylene diisocyanate biuret, hexamethylene diisocyanate biuret (CAS No. 4035-89-6), trimethylene diisocyanate, propylene-1,2-diisocyanate, butylene-1,2-diisocyanate, tetramethylene diisocyanate, pentamethylene diisocyanate, hexamethylene diisocyanate, 4-(isocyanatomethyl)-1,8-octanediisocyanate;

[0090] - A mixture between an aliphatic diisocyanate and an aliphatic triisocyanate,

[0091] - Aromatic polyisocyanates, such as 2,4-toluene diisocyanate, 2,6-toluene diisocyanate, naphthalene diisocyanate, diphenylmethane diisocyanate, triphenylmethane-p,p’,p”-tris(phenylmethyl)trisocyanate,

[0092] - Aromatic isocyanates, such as toluene diisocyanate, polymethylene polyphenyl isocyanate, 2,4,4'-diphenyl ether triisocyanate, polymethylene polyphenyl isocyanate, 2,4,4'-diphenyl ether triisocyanate, 3,3'-dimethyl-4,4'-diphenyl diisocyanate, 3,3-dimethoxy-4,4'-diphenyl diisocyanate, 1,5-naphthalene diisocyanate, 4,4',4”-triphenylmethane triisocyanate, isophorone diisocyanate.

[0093] Select the functional group B' of compound B that contains more than two functional groups B' such that compound B is an amine (such as diamines or polyamines). For example, one or more of the following amines can be used: ethylenediamine, diethylenetriamine, propanediamine, tetraethylenepentamine, pentamethylhexamine, αω-diamine, 1,3-propanediamine, tetramethylenediamine, pentamethylenediamine, 1,6-hexamethylenediamine, triethylenetriamine, pentaethylenehexamine, 1,3-phenylenediamine, 2,4-toluenediamine, 4,4'-diaminodiphenylmethane, 1,5-diaminonaphthalene, 1,3,5-triaminotoluene, 2,4,6-triaminotoluene, 1,3,6-triaminonaphthalene, 2,4,4’-triaminodiphenyl ether, 3,4,5-triamino-1,2,4-triazole, bis(hexamethylenetriamide), 1,4,5,8-tetraaminoanthraquinone.

[0094] A preferred amine is guanidine carbonate.

[0095] According to an advantageous embodiment, the amount of the prepolymer in the oil phase used in the interfacial polymerization method is greater than 25% by volume.

[0096] According to an essential feature of the present invention, the shell that forms the wall around the core accounts for at least 20% of the mass fraction. Advantageously, this fraction is between about 20% and about 45%, more preferably between about 25% and about 35%.

[0097] In the case where some isocyanates result in a relatively hard shell, the mass fraction of the wall around the core advantageously accounts for about 28% to about 32% of the total mass of the microcapsules.

[0098] According to an advantageous aspect of the present invention, the size D of the microcapsules S50 is less than or equal to 0.80 μm. This makes it possible to benefit from the effect unexpectedly discovered by the inventors: for a sunscreen preparation or an anti-photoaging preparation containing a given content of a sunscreen agent, when the D of the microcapsules containing the preparation S50 size is less than or equal to 0.80 μm, the sun protection factor SPF increases. This allows obtaining a higher SPF factor with a given content of the sunscreen preparation, or obtaining a given SPF factor with a lower amount of the sunscreen preparation. Preferably, D S50with a size less than or equal to 0.75 μm, even more preferably less than or equal to 0.70 μm, even more preferably less than or equal to 0.65 μm, or even less than or equal to 0.60 μm, because D S50 with a size less than about 0.8 μm, and as the size of the microcapsules decreases, the SFP factor increases.

[0099] At the end of the third step, a suspension is obtained which comprises a disperse phase (referred to by those skilled in the art as "slurry") and a liquid phase, the disperse phase comprising microcapsules and the liquid phase comprising a solvent, a surfactant, unreacted reagents and various secondary reaction products. In a typical embodiment, the slurry comprises 20% by mass of microcapsules. The microcapsules are washed and concentrated according to methods known to those skilled in the art. After removal of the continuous phase, a suspension can be obtained having microcapsules in an amount greater than 50% by mass, preferably between about 50% and about 70%, even more preferably between about 60% and about 70%, the remainder being water (and various residues). This suspension can be used directly for the preparation of a sunscreen formulation or a photoaging protection formulation incorporating the microcapsules according to the invention; this can be done using known methods, as will be illustrated in the examples. It is also possible to proceed with drying to obtain a microcapsule powder.

[0100] To avoid softening and rupture of the microcapsules, the microcapsules must be introduced with moderate stirring, preferably at a temperature not exceeding the temperature for the preparation of the emulsion (third step of the above method), even more preferably at a temperature below 60 °C.

[0101] Generally, known types of basic ingredients, active ingredients and cosmetic excipients and additives can be used. The nature and amount of the sunscreen used must comply with the current regulations regarding compositions containing sunscreens, which depends on the country of sale. For example, when selling a sunscreen formulation in the United States, the avobenzone concentration must not exceed 3%.

[0102] The microcapsules according to the invention can contain all types of active substances (also referred to as "active ingredients"). For information purposes, a list of active ingredients that can be used as sunscreens and that are preferred for the implementation of the present invention is given here. These active ingredients are identified here by their INCI name (International Nomenclature of Cosmetic Ingredients) and their CAS number:

[0103] Glyceryl PABA (CAS No. 136-44-7), menthyl anthranilate (CAS No. 134-09-8), diethylamino hydroxybenzoyl hexyl benzoate (CAS No. 302776-68-7), polysiloxane-15 (CAS No. 207574-74-1), bis-ethylhexyloxyphenol methoxyphenyl triazine (CAS No. 187393-00-9-6), dimethyl PABA ethylhexyl ester (CAS No. 21245-02-3), ethylhexyl salicylate (CAS No. 11860-5), 3-benzylidene camphor (CAS No. 15087-24-8), diethylhexyl butamido triazone (CAS No. 154702-15-5), 4-methylbenzylidene camphor (CAS No. 38102-62-4 / 36861-47-9), PABA (CAS No. 150-13-0), homosalate (CAS No. 118-56-9), benzophenone-3 (CAS No. 131-57-7), butyl methoxydibenzoylmethane (CAS No. 70356-09-1), octocrylene (CAS No. 6197-30-4), ethylhexyl methoxycinnamate (CAS No. 5466-77-3), isoamyl p-methoxycinnamate (CAS No. 71617-10-2), ethylhexyl triazone (CAS No. 88122-99-0), cresyl triazone (CAS No. 155633-54-8), phenylbis-diphenyltriazine (CAS No. 55514-22-2).

[0104] Stabilizers of known types can be added.

[0105] If at least one of the following components is added to the formulation of the microencapsulated phase, the formulation containing butyl methoxydibenzoylmethane acquires photo-stability: butyl octyl salicylate, C 12-15 alkyl benzoate, diethylhexyl 2,6-naphthalenedicarboxylate, polyester-8, ethylhexyl methoxyacrylate, octocrylene, diethylhexyl subaconyldimalonate, tocopherol, triethyl citrate.

[0106] This results in formulations for sun protection or anti-photoaging that have many advantages. These formulations are highly resistant to spreading on the skin because the microcapsules withstand high shear forces in an aqueous environment when applied to the skin. These formulations minimize the penetration of the sunscreen into the skin because the microcapsules containing the sunscreen are mechanically very stable. For a given concentration of sunscreen, these formulations have a higher sun protection factor. These formulations can be prepared with SPF factors varying over a fairly wide range. The SPF is preferably at least 10, more preferably at least 15, even more preferably at least 30, and still more preferably at least 40. Formulations with an SPF greater than 50 can be prepared.

[0107] Examples

[0108] Example 1 : Preparation of Microcapsules

[0109] In this article, we describe nine examples of embodiments of the method according to the present invention.

[0110] Example 1-1

[0111] Monomer A is an aliphatic polyisocyanate. Monomer B is guanidine carbonate. The active ingredient to be encapsulated is a mixture of butyl methoxydibenzoylmethane (15%), octocrylene (15%) and homosalate (70%).

[0112] Prepare a lipophilic phase, which contains 69.7% of the active ingredient mixture (sunscreen) to be encapsulated, 30% of monomer A and 0.3% of the nonionic surfactant SPAN TM 60. Use 6500 mL of demineralized water, 1% surfactant Texapon TM and 0.3% NaCl to prepare an aqueous continuous phase. Use stoichiometric monomer B to prepare a 500 mL solution.

[0113] Heat the lipophilic phase and the aqueous continuous phase to 60 °C. At this temperature, add the lipophilic phase to be dispersed into the hot continuous phase in a loop containing a rotor stator with very high shear for 6 minutes. The proportion of the lipophilic phase in the aqueous continuous phase containing surfactant is 20%. Then empty the dispersion of the loop into a temperature-controlled tank at 60 °C under constant gentle stirring. Slowly add the solution of monomer B and keep the temperature at 60 °C for at least 6 hours.

[0114] The D X50(表面积) value of the microcapsules is 680 nm.

[0115] Example 1-2

[0116] Monomer A is a mixture of aliphatic polyisocyanate (80%) and polymethylene polyphenyl polyisocyanate (20%). Monomer B is guanidine carbonate. The active ingredient to be encapsulated is a mixture of butyl methoxydibenzoylmethane (13%), ethyl salicylate (22%), homosalate (55%) and propylene carbonate (10%).

[0117] Prepare a lipophilic phase, which contains 69.7% of the active ingredient mixture (sunscreen) to be encapsulated, 30% of monomer A and 0.3% of the nonionic surfactant SPAN TM 60. Use 6500 mL of demineralized water, 0.5% surfactant Texapon TM 、1% surfactant Tween TMPrepare an aqueous continuous phase using 6500 mL of demineralized water, 1% surfactant Tween 20, and 0.1% NaCl. Prepare a 500 mL solution using stoichiometric amounts of monomer B.

[0118] The other steps of the method are carried out as described for Example 1-1: Heat the lipophilic phase and the aqueous continuous phase to 60 °C. At this temperature, add the lipophilic phase to be dispersed into the hot continuous phase in a loop containing a rotor-stator with very high shear for 6 minutes. The proportion of the lipophilic phase in the aqueous continuous phase containing surfactant is 20%. Then empty the dispersion of the loop into a thermostatically controlled bath at 60 °C under constant gentle stirring. Slowly add the monomer B solution and maintain the temperature at 60 °C for at least 6 hours.

[0119] The D X50(表面积) value of the microcapsules is 840 nm.

[0120] Example 1-3

[0121] Monomer A is a mixture of aliphatic polyisocyanate (60%) and polymethylene polyphenyl polyisocyanate (40%). Monomer B is guanidine carbonate. The active ingredient to be encapsulated is a mixture of butyl methoxydibenzoylmethane (15%), diethylhexyl dimethyl PABA (15%), and homosalate (70%).

[0122] Prepare a lipophilic phase containing 69.8% of the active ingredient mixture to be encapsulated (sun protection agent), 30% of monomer A, and 0.2% of the nonionic surfactant SPAN TM 60. Prepare an aqueous continuous phase using 6500 mL of demineralized water, 1% surfactant Tween TM 20 and 0.1% NaCl. Prepare a 500 mL solution using stoichiometric amounts of monomer B.

[0123] Carry out the other steps of the process as described in Example 1-1.

[0124] The D X50(表面积) value of the microcapsules is 720 nm.

[0125] Example 1-4

[0126] Monomer A is a mixture of aliphatic polyisocyanate (90%) and polymethylene polyphenyl polyisocyanate (10%). Monomer B is a mixture of guanidine carbonate (90%) and glycerol (10%). The active ingredient to be encapsulated is a mixture of butyl methoxydibenzoylmethane (13%), ethylhexyl salicylate (18%), homosalate (65%), and tocopheryl acetate (4%).

[0127] Prepare a lipophilic phase that contains 69.7% of the mixture of active ingredients to be encapsulated (sunscreen agents), 30% of monomer A, and 0.3% of the nonionic surfactant SPAN TM 60. Use 6500 mL of demineralized water and 1% surfactant Texapon TM and 0.3% NaCl to prepare an aqueous continuous phase. Use a stoichiometric amount of monomer B to prepare a 500 mL solution.

[0128] Perform the other steps of the process as described in Example 1-1.

[0129] The D X50(表面积) value of the microcapsules is 750 nm.

[0130] Example 1-5

[0131] Repeat Example 1-1 with the following variations: Monomer A is an aliphatic polyisocyanate. Monomer B is guanidine carbonate. The active ingredient to be encapsulated is a mixture of butyl methoxydibenzoylmethane (15%), ethylhexyl triazone (8%), dibutyl adipate (69%), and tocopheryl acetate (8%).

[0132] The D X50(表面积) value of the microcapsules is 450 nm.

[0133] Example 1-6

[0134] Repeat Example 1-1 with the following variations: Monomer A is a mixture of aliphatic polyisocyanate (90%) and polymethylene polyphenyl polyisocyanate (10%). Monomer B is a mixture of guanidine carbonate (90%) and lysine (10%). The active ingredient to be encapsulated is a mixture of butyl methoxydibenzoylmethane (15%), ethylhexyl triazone (7%), dibutyl adipate (55%), ethylhexyl methoxycinnamate (15%), and Polyester-8 (8%).

[0135] The D X50(表面积) value of the microcapsules is 560 nm.

[0136] Example 1-7

[0137] Monomer A is a mixture of aliphatic polyisocyanate (50%) and polymethylene polyphenyl polyisocyanate (50%). Monomer B is guanidine carbonate. The active ingredient to be encapsulated is a mixture of butyl methoxydibenzoylmethane (13%), ethylhexyl triazone (7%), dibutyl adipate (55%), ethylhexyl methoxycinnamate (15%), and triethyl citrate (10%).

[0138] Prepare a lipophilic phase, which contains 69.7% of the active ingredient mixture (sunscreen) to be encapsulated, 30% of monomer A, 1% of surfactant SPAN TM and 1% of surfactant Tween TM 20. Prepare an aqueous continuous phase using 6500 mL of demineralized water and 0.1% NaCl. Prepare a 500 mL solution using stoichiometric monomer B.

[0139] Perform the other steps of the process in combination with those described in Example 1-1.

[0140] The D of the microcapsules X50(表面积) value is 510 nm.

[0141] Example 1-8

[0142] Monomer A is a mixture of aliphatic polyisocyanate (64%) and polymethylene polyphenyl polyisocyanate. Monomer B is guanidine carbonate. The active ingredient to be encapsulated is a mixture of diethylamino hydroxybenzoyl benzoic acid hexyl ester (13%), ethylhexyl triazone (7%), bis-ethylhexyloxyphenol methoxyphenyl triazine (20%) and dibutyl adipate (60%).

[0143] Prepare a lipophilic phase, which contains 69.7% of the active ingredient mixture (sunscreen) to be encapsulated, 30% of monomer A and 0.3% of surfactant SPAN TM 60. Use 6500 mL of demineralized water, 0.1% surfactant Texapon TM 、1% surfactant Tween TM 80 and 0.3% NaCl to prepare an aqueous continuous phase. Prepare a 500 mL solution using stoichiometric monomer B.

[0144] Perform the other steps of the process in combination with those described in Example 1-1.

[0145] The D of the microcapsules X50(表面积) value is 670 nm.

[0146] Example 1-9

[0147] Monomer A is a mixture of aliphatic polyisocyanate (85%) and polymethylene polyphenyl polyisocyanate (15%). Monomer B is guanidine carbonate. The active ingredient to be encapsulated is a mixture of benzophenone-3 (12%), ethylhexyl triazone (8%), dimethyl PABA ethylhexyl ester (20%), 4-methylbenzylidene camphor (20%) and isopropyl palmitate (40%).

[0148] Prepare a lipophilic phase containing 69.7% of the mixture of active ingredients to be encapsulated (sunscreen agents), 30% of monomer A, and 0.1% of the surfactant SPAN TM 60. Use 6500 mL of demineralized water and 1% of the surfactant Texapon TM and 0.5% NaCl to prepare an aqueous continuous phase. Use a stoichiometric amount of monomer B to prepare a 500 mL solution.

[0149] Perform the other steps of the process as described in Example 1-1.

[0150] Example 2 : Particle size determination of microcapsules 110 and 108

[0151] Dilute the aqueous suspension and the surfactant containing the microcapsules according to the present invention with demineralized water and analyze using a Mastersizer TM 3000 particle size analyzer (Malvern). The results for microcapsule 108 are reported in Figure 1 where the instrument provides different representations (volume; surface area; number). All distributions are unimodal. This indicates that the dispersion of the microcapsules is quite uniform, although the difference between "number" and "volume" indicates a significant degree of polydispersity in the microcapsule size. In all cases, the average size of the microcapsules is between 200 nm and 800 nm.

[0152] The results for sample 110 are reported in Figure 2 In this case, the distribution has a quasi-bimodal trend (a shoulder at 500 nm in the volume distribution; two Gaussian distributions superimposed in the surface area distribution), which indicates a greater polydispersity in terms of size compared to sample 110, thus distinguishing two families of microcapsules with significantly different sizes. This is clearly visible in the surface area distribution, where the two peaks coincide with the medians of the number (smaller size) and volume (larger size) distributions.

[0153] To better see the difference in the fine dispersion fractions between samples 110 and 108, the surface area distributions were compared, and the results are reported in Figure 3 It can be clearly seen that compared to microcapsule 110, microcapsule 108 has a significantly smaller average surface area and a more uniform distribution.

[0154] The laser particle size determination results for samples 110 and 108 show that these two types of microcapsules have a very fine particle size distribution (above microns). Compared to microcapsule 110, microcapsule 108 has a more uniform and finer particle size distribution, which can give them greater effectiveness in UV protection when used in cosmetic formulations.

[0155] These results also indicate that laser granulometry can be used to determine the average size of microcapsules in a colloidal dispersion. This is a rapid and inexpensive method compared to electron microscopy.

[0156] A laser particle size analyzer is capable of measuring the particle size distribution of particles in a colloidal dispersion using laser diffraction. The particle size can be described in several ways: the maximum length of the particle, the minimum length of the particle, the volume of the particle, the surface area of the particle. Therefore, depending on the analytical technique used, the particle size distribution of a colloidal dispersion can also be represented in different modes:

[0157] 1) Number (D[1,0]): weighted to the minimum size (more used in microscopy) ( Figure 1 )

[0158] 2) Volume (D[4,3]): weighted to the maximum size (more used in laser diffraction) ( Figure 1 )

[0159] 3) Surface area (D[3,2]): median between number and volume.

[0160] When focusing on the coarse dispersion fraction, volume representation is usually used to observe the differences between two colloidal dispersions. On the other hand, when we want to know the differences in the fine dispersion fraction, surface area representation is more used, especially in applications where the surface area of the dispersed particles is important (drugs; cosmetics; paints).

[0161] Typically, in a laser granulometer, the sample continuously passes through the laser analysis chamber under suction. The laser scattered by the sample is intercepted by detectors located at different angles around the sample. This type of configuration allows for the differentiation of different particle size families in a colloidal dispersion, since smaller particles scatter the laser at a larger angle compared to larger particles. To avoid detector saturation, the sample must have an appropriate dilution.

[0162] Example 3 : Relationship between the particle size of microcapsule 110 and the SPF factor

[0163] The sample analyzed was a slurry of microcapsules 110, which contained a mixture of UV filters meeting the requirements of the US FDA at 20% by mass. The microcapsules were synthesized from different emulsions prepared by a rotor-stator with different shear rates. These emulsions were then converted into microcapsules by an interfacial polymerization method. Thus, different microcapsule slurries characterized by particle size measurements were obtained, which could be weighted by number, surface area, volume or mass.

[0164] Using Mastersizer TMThe diameter size was measured using a 3000 particle size analyzer (Malvern). Before each measurement, the starting sample was diluted with demineralized water until the optimal saturation level of the optical detector was reached. Three replicate measurements were performed on each labeled sample. The obtained particle sizes can be processed in three different ways: volume, number, and surface area.

[0165] In this study, the results of the surface area-weighted particle size of D S50 were retained.

[0166] The median size or D S50 size is the size at which the cumulative function equals 50%; it is surface area-weighted. When studying the activity of a certain dispersed component (paint; catalyst; medicine), the choice of surface area-weighting is the most relevant.

[0167] To correlate D S50 with SPF, an in vitro method on PMMA plates was used to measure the SPF of these same samples.

[0168] The results are reported in Figure 4 and Table 1.

[0169] Table 1

[0170]

[0171] Figure 4 A curve representing the measured SPF as a function of the median diameter (D S50 ) of the microcapsule slurry.

[0172] The results clearly show that when the D S50 of the microcapsules decreases, the SPF value of the suspension increases. As shown by the interpolation curve (red line), when the surface area-weighted median diameter (D S50 ) is less than 800 nm, this effect is exponential and results in a good SPF (relative to the amount of encapsulated filter agent).

[0173] These results indicate that when the suspension contains finely dispersed microcapsules, for the same application surface, they can absorb UV rays more effectively and thus better prevent the harmful effects of these same rays. Therefore, for products containing sunscreen microcapsules, this property is essential for obtaining products that perform well in terms of effectiveness (SPF).

[0174] Example 4 : Characterization of the ζ-potential of the colloidal suspension

[0175] In this study, the four samples analyzed were suspensions containing 20% microcapsules (MC) 110. Each sample was prepared using different amounts of NaCl: 0% (110A), 0.35% (110B), 0.7% (110C), and 1.4% (110D).

[0176] For ζ-potential measurements, the suspension containing microcapsules 110 was pre-diluted 1000-fold with demineralized water to obtain a clear and transparent dispersion suitable for analysis. Each sample was measured three times in duplicate using a Malvern Zetasizer Nano (Malvern Instruments).

[0177] Diameter size measurements were performed using a Mastersizer 3000 particle sizer (Malvern). Before each measurement, the starting sample was diluted with demineralized water until the optimal saturation level of the optical detector was reached. The particle sizes obtained could be weighted according to three different modes: volume, number, and surface area. In this study, the D S50 parameter of the surface area-weighted particle size determination (see Figure 6 ) and the D V50 parameter of the volume-weighted particle size determination (see Figure 5 ) were retained. In Figure 5 , 6 , and 7, curve (a) corresponds to sample 110A, curve (b) corresponds to sample 110B, curve (c) corresponds to sample 110C, and curve (d) corresponds to sample 110D.

[0178] Figure 7 The ζ-potential results in clearly show a significant increase in the charge on the surface of the microcapsules from -40 mV to -66 mV in the presence of salt during the synthesis process. However, this increase weakly depends on the NaCl concentration, i.e., the change in charge with salt concentration is very small (0.35%; -67 mV; sample 110B) and maximum (1.4%; -74 mV; sample 110D).

[0179] Figure 5 and 6 The particle size results presented in clearly indicate that the increase in surface charge is due to the presence of salt; however, the particle size distribution of the microcapsules is independent or almost independent of the presence of salt. Both the surface area and volume distributions have a bimodal distribution, indicating the presence of two families of microcapsules with average sizes of approximately 0.6 μm and 1.3 μm. When the NaCl concentration reaches 1.4%, the more finely dispersed family of microcapsules becomes the majority.

[0180] This example shows that the presence of NaCl increases the negative ζ-potential on the surface of the microcapsules, regardless of the concentration of the salt tested.

[0181] Therefore, the stability of the microcapsule suspension is directly affected by the presence of salts during the synthesis process. Stronger surface charges stabilize the microcapsule dispersion by promoting electrostatic repulsion and minimizing aggregation effects. This effect can be achieved at low salt concentrations (0.35%). This explains why more concentrated and aggregate-free suspensions can be obtained when salts are added during the synthesis of the suspension.

[0182] Example 5 : Study on the photostability of the UV filter composition according to the present invention

[0183] The results were obtained using a specific in vitro method for determining the SPF sun protection index, UVA protection, and calculating the critical wavelength (abbreviated as LOC) on a polymethyl methacrylate (PMMA) carrier of a sunscreen panel.

[0184] Using a Kontron TM 933 spectrophotometer equipped with an integrating sphere TM 933 spectrophotometer, four measurements were made to determine the sun protection factor. Using No.1, No.2, No.3 and No.5 methods to determine the SPF, UVA, and LOC values and evaluate the photostability.

[0185] Solar radiation tests were carried out using a Suntest Atlas CPS+ simulator at 550 W / m 2 at 30-minute intervals; the correspondence with the DEM unit (minimum erythema dose) is: 30 min = 4 DEM; 60 min = 8 DEM; 120 min = 16 DEM. As is known to those skilled in the art, the DEM unit represents the minimum amount of light that can trigger sunburn at the exposed location after 24 hours.

[0186] The results were collected in Table 2 below and Figure 8 and 9 in.

[0187] Table 2

[0188]

[0189] Figure 8Shows the variation of the SPF factor as a function of the concentration of the UV filter in the core of the microcapsules, and compares the encapsulated samples with a sunscreen content of 23% according to the invention (curve (c): UV-A; curve (d): IIV-B) relative to the total mass of the microcapsules with the same non-encapsulated active substance contained in the fatty phase according to the state of the art (curve (a): UV-A; curve (b): UV-B). The vertical axis represents the SPF value (100% being the initial value), and the horizontal axis represents the number of 30-minute irradiation cycles.

[0190] It should be noted that the fatty phase is unstable under UV irradiation: this instability is complete after irradiation for two hours (16 DEM) at 550 W / m 2 The suspension is stable during the first irradiation and then shows a very significant instability after irradiation for two hours (16 DEM) at 550 W / m 2 The encapsulation of the UV filter improves the light stability of the formulation in terms of the SPF factor and UV-A protection.

[0191] Figure 9 Shows the same type of curves representing microcapsules with a sunscreen content of 35%. The curves refer to the microencapsulated formulation according to the invention (curve (c): UV-A; curve (d): UV-B) and the fatty formulation without microcapsules according to the prior art (curve (a): UV-A; curve (b): UV-B).

[0192] The observations regarding the light stability of the fatty phase and the suspension are the same as in the above figure. The fatty phase is unstable under UV irradiation: this instability is complete after irradiation for two hours (16 DEM) at 550 W / m 2 The suspension is stable during the first irradiation and then shows a very significant instability after irradiation for two hours (16 DEM) at 550 W / m 2 The encapsulation of the UV filter improves the light stability of the formulation in terms of the SPF factor and UV-A protection.

[0193] Figure 10 Shows the variation of the SPF factor measured for the microencapsulated suspension composition according to the invention (curve (a)), the non-microencapsulated suspension composition not according to the invention (curve (b)), and the compositions containing different concentrations of the UV filter. It should be noted that at concentrations above approximately 21% to 22%, the microencapsulated suspension shows significantly higher protective activity than the non-encapsulated suspension, while no difference is observed for lower concentrations.

[0194] Example 6 : In vitro skin absorption comparison of encapsulated and non-encapsulated forms of the sunscreen

[0195] A microcapsule suspension using microcapsules concentrated at 33% in water and containing 23% of the encapsulated sunscreen according to the present invention, and a control of the non-encapsulated sunscreen diluted at 23% in a product sold under the trademark Cétiol Ultimate (undecane / tridecane mixture).

[0196] Human skin explants were used on Transwell inserts mounted in 6-well plates. The treated area was 1 cm 2 . The receiving fluid was PBS (1 mL). The treatment volume was 10 μL / cm 2 , and the treatment duration was 24 hours at 37 °C.

[0197] The following three different treatments were used: a control treatment (without active ingredient), an encapsulated formulation according to the present invention, and a non-encapsulated formulation not according to the present invention.

[0198] At the end of the treatment, excess formulation was removed using a cotton swab. Biopsy specimens were obtained from the treated surface using a 100 mm diameter punch. The biopsy specimens were cut in half using a scalpel, mounted in a freezing matrix, and placed on a cryobar at -50 °C, and then mounted on a cutting support. Sections with a thickness of 5 μm were cut from each sample using a cryostat.

[0199] The sections were observed under a fluorescence microscope using a DAPI filter at magnifications of 10 and 20. The exposure time for image acquisition was 20 ms. Image analysis was performed using ImageJ software, which allows semi-quantitative analysis of fluorescence intensity.

[0200] Figure 11 Fluorescence micrographs of three samples (two different regions of each treated sample) obtained at a magnification of 20 are shown.

[0201] Figure 12 Fluorescence signals (in arbitrary units) obtained by image analysis at magnifications of 10 and 20 for the three samples are shown. More specifically, Figure 12 Fluorescence signals at magnifications of 20 (right) and 10 (left) are shown Figure 11 for the total intensity of the images in.

[0202] For the untreated control samples, a diffuse fluorescence signal corresponding to the autofluorescence of the skin was observed.

[0203] Regarding the samples treated with the non-encapsulated formulation, image analysis showed that the fluorescence intensity (diffuse signal) was slightly higher compared to the control samples.

[0204] Regarding samples treated with the encapsulation preparation according to the present invention, the signal is at the level of the stratum corneum. The fluorescence intensity is much higher compared to untreated control samples and samples treated with non-encapsulated preparations; thus, the signal is specific for the preparation according to the present invention.

[0205] Example 7 : Example of a carrier preparation for a sunscreen

[0206] Example 7-1 :

[0207] The preparation is based on the following components:

[0208]

[0209]

[0210] For this test, a planetary stirrer was used, but no homogenizer. The components of phase A were cooled without using a homogenizer. Then, without using a homogenizer still, the components of phase B were dispersed in phase A, and then the components of phase C, previously fully dissolved, were added. Phase D was heated to 80 °C to fully mix its components, then phase E (not heated) was added to phase D, and then this mixture of phase D and phase E was introduced into the prepared mixture consisting mainly of phase A without using a homogenizer still. Then, without using a homogenizer still, phase F and phase G were introduced. Phase H was added to adjust the pH to a value of about 6.

[0211] Example 7-2 :

[0212] The preparation is based on the following components:

[0213] Phase Ingredients according to INCI nomenclature % by mass A Suspension of microcapsules according to the invention, 60% 55 A Citric acid 0.1 B Xanthan gum 0.1 B Hydroxypropyl guar gum 0.15 C Water 8.85 C Disodium edetate 0.05 D Sodium stearoyl glutamate 1 E Cetyl alcohol 1 E Sucrose poly stearate, cetyl palmitate 3 E Dicaprylyl carbonate, tocopherol 12 E Squalane 5 E Shea (Butyrospermum Parkii) butter 2 E Behenyl PVP 2 F Undecane, tridecane, tocopherol 8 G Tocopherol, sunflower seed oil 0.5 H Phenoxyethanol, ethylhexylglycerin 1 I Citric acid 0.25

[0214] For this test, a planetary stirrer was used, but no homogenizer. The components of phase A were cooled without using a homogenizer. Then, without using a homogenizer still, the components of phase B were dispersed in phase A, then the components of phase C, previously fully dissolved, were added, and then phase D was added. Phase E was heated to 80 °C to fully mix its components, then it was added to phase F (not heated), and then this mixture of phase E and phase F was introduced into the prepared mixture consisting mainly of phase A without using a homogenizer still. Then, without using a homogenizer still, phase G and phase H were introduced. Phase I was added to adjust the pH to a value of about 6.

[0215] Example 7-3 :

[0216] The preparation is based on the following components:

[0217] Phase Ingredients according to INCI nomenclature % by mass A Water 53.65 A Disodium edetate 0.1 A Glycerol 5 B Polyacrylate crosslinked polymer-6 1.5 C Aqueous acrylate copolymer 2 D Suspension of microcapsules according to the invention, 99% 33 E Phenoxyethanol, ethylhexylglycerin 1 E Tocopherol, sunflower seed oil 0.5 F Polydimethylsiloxane 3 G Citric acid 0.25

[0218] For this test, a planetary mixer is used, but no homogenizer. The components of phase A are cooled and mixed, and then the components of phase B are dispersed in phase A under vigorous stirring, and then phase C is added. Phase D is added to this mixture without using a homogenizer. Then, without using a homogenizer, the components of phase E are mixed and phase E is introduced into the prepared mixture mainly composed of phase A. Then, still without using a homogenizer, phase E is slowly introduced under strong planetary stirring. Phase I is added to adjust the pH to a value of about 6.

[0219] Example 7-4 :

[0220] This preparation is based on the following components:

[0221]

[0222]

[0223] The components of phase A are cooled and mixed, and then the components of phase B are dispersed in phase A under vigorous stirring; for this purpose, it is advantageous to use a homogenizer. Then phase C is added under the same conditions. The remaining part of the process is carried out without a homogenizer and planetary stirring. Then phase D is introduced. Then the components of phase E are mixed and phase E is introduced into the prepared mixture under planetary stirring without using a homogenizer. Then the components of phase E are mixed and phase E is introduced into the prepared mixture mainly composed of phase D without using a homogenizer. Then, still without using a homogenizer, phase F is slowly introduced under vigorous planetary stirring. Phase G is added to adjust the pH to a value of about 6.

Claims

1. A core-shell microcapsule, the core-shell microcapsule comprising a core and a shell, the core containing at least one active ingredient, the shell forming a wall surrounding the core and accounting for at least 20%, preferably at least 25%, more preferably at least 30%, even more preferably at least 35% of the total mass of the microcapsule by mass fraction, the microcapsule being characterized in that the shell contains at least one crosslinked polymer, and the at least one crosslinked polymer is preferably obtained by interfacial polymerization.

2. The core-shell microcapsule according to claim 1, wherein The at least one crosslinked polymer is selected from polyurethane and / or polyurea.

3. The core-shell microcapsule according to claim 1 or 2, characterized in that, The shell contains at least one anionic surfactant and / or at least one nonionic surfactant, the anionic surfactant being preferably alkyl ether sulfate, and the at least one nonionic surfactant being preferably selected from the group consisting of polyethylene glycol esters, polyethylene glycol ethers, polyglycerol esters, esters of sorbitol derivatives such as sorbitan stearate, sucrose esters, polysorbates such as polysorbate 20, polysorbate 40 or polysorbate 60, and polysorbate 20 being the preferred nonionic surfactant.

4. The core-shell microcapsule according to any one of claims 1 to 3, the average size D of the core-shell microcapsule S50 is less than 1.0 μm, preferably less than 0.80 μm, more preferably less than 0.70 μm, and even more preferably less than 0.60 μm.

5. The core-shell microcapsule according to any one of claims 1 to 4, characterized in that, The active ingredient is selected from sunscreen agents.

6. A sunscreen preparation or anti-photoaging preparation, the sunscreen preparation or anti-photoaging preparation comprising a plurality of core-shell microcapsules according to any one of claims 1 to 5.

7. The sunscreen preparation or anti-photoaging preparation according to claim 6, characterized in that, Relative to the total weight of the preparation, the sunscreen preparation or anti-photoaging preparation contains at least 5%, preferably at least 20%, more preferably at least 30%, even more preferably at least 35% by mass of the core-shell microcapsules.

8. The sunscreen preparation according to claim 6 or claim 7, characterized in that, The sun protection factor of the sunscreen preparation is at least 10, preferably at least 15, more preferably at least 30, even more preferably at least 40, and optimally at least 50.

9. Use of the core-shell microcapsules according to any one of claims 1 to 5 in the preparation of a sunscreen preparation or a product for providing protection against photoaging of the skin or skin appendages, which can be used in the following forms: in the form of a liquid or pasty emulsion such as an ointment, cream, lotion, foam; or in the form of a solid emulsion such as a stick, bar, loaf; or in a non-emulsified form such as an oil, suspension, gel, lotion, loose or dense powder.

10. A method for preparing core-shell microcapsules by interfacial polymerization, the core-shell microcapsules comprising a core and a shell, the core containing at least one active ingredient, the shell forming a wall surrounding the core and accounting for at least 20%, preferably at least 30%, even more preferably at least 35% of the total mass of the microcapsule by mass fraction, and the shell containing at least one crosslinked polymer obtained from at least two precursor compounds A and B, the method comprising the following steps: (a) Mixing the at least one active ingredient, a solvent and at least one compound A containing more than two functional groups A' to obtain a lipophilic phase; (b) Introducing the lipophilic phase obtained in step (a) into an aqueous continuous phase with stirring to form an emulsion, and the aqueous continuous phase preferably contains NaCl; (c) The emulsion is maintained at a temperature between about 35 °C and about 90 °C, preferably between about 40 °C and about 70 °C, even more preferably between about 55 °C and about 65 °C, with stirring, and an aqueous solution containing at least one compound B comprising more than two functional groups B' is introduced into the emulsion obtained at the end of step (b) with stirring, so that the functional groups A' of the compound A comprising more than two functional groups A' react with the functional groups B' of the compound B comprising more than two functional groups B' to form a crosslinked polymer shell constituting the wall around the core, thereby obtaining core-shell microcapsules.

11. The method for preparing core-shell microcapsules by interfacial polymerization according to claim 10, characterized in that, The stirring during step (b) is carried out at a tangential velocity greater than that during the introduction of the aqueous solution containing at least one compound B in step (c), and preferably at a tangential velocity of at least 10 m / s, preferably between 10 m / s and 30 m / s.

12. The method for preparing core-shell microcapsules by interfacial polymerization according to claim 11, wherein, The aqueous continuous phase contains at least one anionic surfactant and / or one non-ionic surfactant, and the anionic surfactant is preferably selected from alkyl ether sulfates, and even more preferably selected from magnesium lauryl polyether sulfate and sodium lauryl polyether sulfate.

13. The method for preparing core-shell microcapsules by interfacial polymerization according to any one of claims 10 to 12, characterized in that, The NaCl content in the emulsion obtained in step (b) is between 0.10% and 1% by mass, preferably between 0.15% and 0.90% by mass.

14. The method for preparing core-shell microcapsules by interfacial polymerization according to any one of claims 10 to 13, characterized in that: - The functional groups A' of the compound A comprising more than two functional groups A' are selected from isocyanate groups, and the compound A is preferably selected from the group consisting of: ○ Dicyclohexylmethane 4,4'-diisocyanate, hexamethylene 1,6-diisocyanate, isophorone diisocyanate, trimethyl-hexamethylene diisocyanate, trimer of hexamethylene 1,6-diisocyanate, trimer of isophorone diisocyanate, 1,4-cyclohexane diisocyanate, 1,4-(dimethylisocyanatocyclohexane), hexamethylene diisocyanate biuret, hexamethylene diisocyanate biuret (CAS No. 4035-89-6), trimethylene diisocyanate, propylene-1,2-diisocyanate, butylene-1,2-diisocyanate, tetramethylene diisocyanate, pentamethylene diisocyanate, hexamethylene diisocyanate, 4-(isocyanatomethyl)-1,8-octanediisocyanate; O A mixture between an aliphatic diisocyanate and an aliphatic triisocyanate, ○ Aromatic polyisocyanates, such as 2,4-toluene diisocyanate, 2,6-toluene diisocyanate, naphthalene diisocyanate, diphenylmethane diisocyanate, triphenylmethane - p,p',p''-tris(phenylmethyl) trisocyanate, ○ Aromatic isocyanates, such as tolylene diisocyanate, polymethylene polyphenyl isocyanate, 2,4,4'-diphenyl ether triisocyanate, polymethylene polyphenyl isocyanate, 2,4,4'-diphenyl ether triisocyanate, 3,3'-dimethyl-4,4'-diphenyl diisocyanate, 3,3-dimethoxy-4,4'-diphenyl diisocyanate, 1,5-naphthalene diisocyanate, 4,4',4''-triphenylmethane triisocyanate, isophorone diisocyanate; - Select the functional group B' of compound B that contains more than two functional groups B', such that compound B is an amine, and is preferably selected from the group consisting of: ethylenediamine, diethylenetriamine, propanediamine, tetraethylenepentamine, pentamethylhexamine, αω-diamine, 1,3-propanediamine, tetramethylenediamine, pentamethylenediamine, 1,6-hexamethylenediamine, triethylenetriamine, pentaethylenehexamine, 1,3-phenylenediamine, 2,4-toluenediamine, 4,4'-diaminodiphenylmethane, 1,5-diaminonaphthalene, 1,3,5-triaminotoluene, 2,4,6-triaminotoluene, 1,3,6-triaminonaphthalene, 2,4,4'-triaminodiphenyl ether, 3,4,5-triamino-1,2,4-triazole, bis(hexamethyltriamide), 1,4,5,8-tetraaminoanthraquinone'.

15. The method for preparing core-shell microcapsules by interfacial polymerization according to any one of claims 10 to 14, characterized in that, The crosslinked polymer is selected from polyureas or polyurethanes.

Citation Information

Patent Citations

  • Match box

    CA118569A

  • Horse detacher

    CA118605A

  • Apparatus for producing continuous electric ares

    CA131577A

  • Curling iron

    CA134098A

  • Sill for hay racks

    CA136447A

Cited By

  • Safe sunscreen microcapsule coating composition, microcapsule coating method, cosmetic and application

    CN122005341A